May, 09 2025 Friday 20:13 Hrs
  • SENSEX :   79,454.47

  • Top commodity trading and broking companies in India-880.34( -1.10%) 09-May-2025
top-arrow-market
Sensex 79454.47 -880.34  (-1.10) 09-May-2025
Previous Day Close
80334.81
Today's High/Low
High Low
  •  
  •  
80032.93 78968.34

Company News Details

Sun Pharmaceutical Industries Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524715
INE044A01036
98.3315118
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SUNPHARMA
134.52
423770.54
EPS(TTM)
Face Value()
Div & Yield %
13.13
1
0.76
 

Sun Pharmaceutical Industries Ltd
Sun Pharma launches Fexuprazan tablets 40 mg in India
Apr 07,2025
The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosive esophagitis of all grades. FEXUCLUE, containing Fexuprazan, is primarily used to treat acid-related disorders, including gastroesophageal reflux disease (GERD) and erosive esophagitis. It is also being studied for the prevention of NSAID-induced peptic ulcers and gastritis.

Sun Pharma has obtained the rights from Daewoong Pharmaceutical, a South Korean biopharmaceutical company, to manufacture and commercialize FEXUCLUE in India. As part of the agreement, Daewoong will receive upfront and milestone payments, as well as royalties.

Kirti Ganorkar, CEO of India Business, Sun Pharma, said, “Erosive esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. FEXUCLUE is a best-in-class treatment option with the potential to bridge this gap. At Sun Pharma, we are committed to introducing innovative medicines that enhance patients' quality of life.'

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with a specialty and generic presence and India's top pharma company.

The pharma major’s consolidated net profit increased 15.04% to Rs 2,903.38 crore on a 10.46% rise in revenue from operations to Rs 13,675.46 crore in Q3 FY25 over Q3 FY24.

Shares of Sun Pharmaceuticals Industries fell 3.47% to Rs 1,650 on the BSE.

Top
Attention Investor:
Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers/Depository Participant.     KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, ,Mutual ).    No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.